Insight Molecular Diagnostics Inc. (IMDX) - Net Assets
Based on the latest financial reports, Insight Molecular Diagnostics Inc. (IMDX) has net assets worth $-9.20 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($43.94 Million) and total liabilities ($53.13 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Insight Molecular Diagnostics Inc. to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-9.20 Million |
| % of Total Assets | -20.93% |
| Annual Growth Rate | N/A |
| 5-Year Change | -136.66% |
| 10-Year Change | -217.83% |
| Growth Volatility | 260.9 |
Insight Molecular Diagnostics Inc. - Net Assets Trend (2013–2024)
This chart illustrates how Insight Molecular Diagnostics Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore how large is Insight Molecular Diagnostics Inc.'s balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Insight Molecular Diagnostics Inc. (2013–2024)
The table below shows the annual net assets of Insight Molecular Diagnostics Inc. from 2013 to 2024. For live valuation and market cap data, see Insight Molecular Diagnostics Inc. market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-12.27 Million | -159.97% |
| 2023-12-31 | $20.47 Million | -48.31% |
| 2022-12-31 | $39.59 Million | -39.29% |
| 2021-12-31 | $65.22 Million | +94.78% |
| 2020-12-31 | $33.48 Million | +8.58% |
| 2019-12-31 | $30.84 Million | +800.91% |
| 2018-12-31 | $3.42 Million | -22.26% |
| 2017-12-31 | $4.40 Million | -55.35% |
| 2016-12-31 | $9.86 Million | -5.33% |
| 2015-12-31 | $10.42 Million | +1069.93% |
| 2014-12-31 | $-1.07 Million | -129.71% |
| 2013-12-31 | $3.62 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Insight Molecular Diagnostics Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 34012600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $338.24 Million | % |
| Other Comprehensive Income | $21.00K | % |
| Total Equity | $-12.27 Million | 100.00% |
Insight Molecular Diagnostics Inc. Competitors by Market Cap
The table below lists competitors of Insight Molecular Diagnostics Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kumpulan Kitacon Berhad
KLSE:5310
|
$86.68 Million |
|
Yojee Ltd
AU:YOJ
|
$86.77 Million |
|
Sergeferrari G
PA:SEFER
|
$86.82 Million |
|
GBM Resources Limited
AU:GBM
|
$86.83 Million |
|
Mangold Fondkommission AB
ST:MANG
|
$86.65 Million |
|
Gowing Bros Ltd
AU:GOW
|
$86.57 Million |
|
Pyxis Oncology Inc
NASDAQ:PYXS
|
$86.55 Million |
|
Valuence Merger Corp I
NASDAQ:VMCA
|
$86.52 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Insight Molecular Diagnostics Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 20,468,000 to -12,274,000, a change of -32,742,000 (-160.0%).
- Net loss of 60,663,000 reduced equity.
- Share repurchases of 5,389,000 reduced equity.
- New share issuances of 27,814,000 increased equity.
- Other comprehensive income decreased equity by 28,000.
- Other factors increased equity by 5,524,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-60.66 Million | -494.24% |
| Share Repurchases | $5.39 Million | -43.91% |
| Share Issuances | $27.81 Million | +226.61% |
| Other Comprehensive Income | $-28.00K | -0.23% |
| Other Changes | $5.52 Million | +45.01% |
| Total Change | $- | -159.97% |
Book Value vs Market Value Analysis
This analysis compares Insight Molecular Diagnostics Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $11.14 | $4.18 | x |
| 2014-12-31 | $-0.99 | $4.18 | x |
| 2015-12-31 | $9.92 | $4.18 | x |
| 2016-12-31 | $7.43 | $4.18 | x |
| 2017-12-31 | $2.92 | $4.18 | x |
| 2018-12-31 | $1.81 | $4.18 | x |
| 2019-12-31 | $12.02 | $4.18 | x |
| 2020-12-31 | $10.23 | $4.18 | x |
| 2021-12-31 | $14.67 | $4.18 | x |
| 2022-12-31 | $7.15 | $4.18 | x |
| 2023-12-31 | $2.68 | $4.18 | x |
| 2024-12-31 | $-0.94 | $4.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Insight Molecular Diagnostics Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3225.04%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-147.83%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -96.68% | 0.00% | 0.00x | 2.29x | $-3.86 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.88 Million |
| 2015 | -83.85% | 0.00% | 0.00x | 1.22x | $-9.78 Million |
| 2016 | -113.24% | 0.00% | 0.00x | 1.46x | $-12.15 Million |
| 2017 | -440.04% | 0.00% | 0.00x | 2.32x | $-19.82 Million |
| 2018 | -460.24% | 0.00% | 0.00x | 2.78x | $-16.10 Million |
| 2019 | -72.41% | 0.00% | 0.00x | 1.29x | $-25.41 Million |
| 2020 | -89.39% | -2461.51% | 0.02x | 1.66x | $-33.28 Million |
| 2021 | -98.28% | -2916.15% | 0.01x | 2.45x | $-70.62 Million |
| 2022 | -184.12% | -7609.81% | 0.01x | 2.53x | $-76.86 Million |
| 2023 | -135.73% | -1848.37% | 0.02x | 3.66x | $-29.83 Million |
| 2024 | 0.00% | -3225.04% | 0.05x | 0.00x | $-59.44 Million |
Industry Comparison
This section compares Insight Molecular Diagnostics Inc.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $543,908,184
- Average return on equity (ROE) among peers: -221.59%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | $-9.20 Million | -96.68% | N/A | $86.66 Million |
| Agilent Technologies Inc (A) | $2.51 Billion | -1.24% | 2.04x | $32.42 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.49 Million | -115.35% | 0.92x | $7.19 Million |
| Applied DNA Sciences Inc (APDN) | $11.11 Million | -144.24% | 0.30x | $3.99 Million |
| Biodesix Inc (BDSX) | $4.58 Million | -1138.56% | 20.64x | $79.44 Million |
| bioAffinity Technologies, Inc. (BIAF) | $7.28 Million | -204.87% | 0.51x | $9.85 Million |
| Biocept Inc. (BIOCQ) | $11.20 Million | -224.43% | 0.58x | $262.00 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $30.47 Million | -271.32% | 5.29x | $3.21 Billion |
| Burning Rock Biotech Ltd (BNR) | $2.42 Billion | -16.82% | 0.10x | $154.44 Million |
| CareDx Inc (CDNA) | $430.91 Million | -17.78% | 0.26x | $1.00 Billion |
| Check Cap Ltd (CHEK) | $13.03 Million | -81.27% | 0.18x | $9.42 Million |
About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expre… Read more